2023 Drugs Adverse Effect ICD-10-CM Codes
When coding adverse effect due to the improper use of a medication or substance first assign the appropriate code from the 168 total codes in the ICD-10-CM Table of Drugs and Chemicals. No additional external cause code is required for poisonings, toxic effects, adverse effects and underdosing codes.
ICD Code | Description | Category | Applicable To |
---|---|---|---|
T36.0X5 | Adverse effect of penicillins | Systemic antibiotics (T36) | Adicillin; Amdinocilline; Amoxicillin; Ampicillin; Ancillin; Apalcillin; Aspoxicillin; Azidocillin; Azlocillin; Bacampicillin; Benethamine penicillin; Benzathine benzylpenicillin; Benzathine penicillin; Benzylpenicillin; Carbenicillin; Carfecillin; Carindacillin; Ciclacillin; Clometocillin; Cloxacillin; Cyclacillin; Dicloxacillin; Epicillin; Flucloxacillin; Hetacillin; Hydrabamine penicillin; Imip... |
T36.1X5 | Adverse effect of cephalosporins and other beta-lactam antibiotics | Systemic antibiotics (T36) | Aztreonam; Cefacetrile; Cefaclor; Cefadroxil; Cefalexin; Cefaloglycin; Cefaloridine; Cefalosporins; Cefalotin; Cefamandole; Cefamycin antibiotic; Cefapirin; Cefatrizine; Cefazedone; Cefazolin; Cefbuperazone; Cefetamet; Cefixime; Cefmenoxime; Cefmetazole; Cefminox; Cefonicid; Cefoperazone; Ceforanide; Cefotaxime; Cefotetan; Cefotiam; Cefoxitin; Cefpimizole; Cefpiramide; Cefradine; Cefroxadine; Cefs... |
T36.2X5 | Adverse effect of chloramphenicol group | Systemic antibiotics (T36) | Chloramphenicol; ChloramphenicolENT agent; Chloramphenicolophthalmic preparation; Chloramphenicoltopical NEC; Chloromycetin; ChloromycetinENT agent; Chloromycetinophthalmic preparation; Chloromycetinotic solution; Chloromycetintopical NEC; Cloponone; Cloramfenicol; Thiamphenicol |
T36.3X5 | Adverse effect of macrolides | Systemic antibiotics (T36) | Azithromycin; Erythromycin (salts); Erythromycin (salts)ophthalmic preparation; Erythromycin (salts)topical NEC; Ilotycin; Ilotycinophthalmic preparation; Ilotycintopical NEC; Josamycin; Kitasamycin; Midecamycin; Miokamycin; Oleandomycin; Pristinamycin; Rokitamycin; Roxithromycin; Spiramycin; TAO; Triacetyloleandomycin; Troleandomycin |
T36.4X5 | Adverse effect of tetracyclines | Systemic antibiotics (T36) | Achromycin; Achromycinophthalmic preparation; Achromycintopical NEC; Aureomycin; Aureomycinophthalmic preparation; Aureomycintopical NEC; Chlormethylenecycline; Chlortetracycline; Clomocycline; Declomycin; Demeclocycline; Demethylchlortetracycline; Demethyltetracycline; DMCT; Doxycycline; Guamecycline; Lymecycline; Meclocycline; Metacycline; Methacycline; Minocycline; Oxytetracycline; Penimepicycl... |
T36.5X5 | Adverse effect of aminoglycosides | Systemic antibiotics (T36) | Amikacin; Astromicin; Bekanamycin; Dibekacin; Dihydrostreptomycin; Framycetin; Garamycin; Garamycinophthalmic preparation; Garamycintopical NEC; Gentamicin; Gentamicinophthalmic preparation; Gentamicintopical NEC; Isepamicin; Kanamycin; Kantrex; Micronomicin; Mycifradin; Mycifradintopical; Neomycin (derivatives); Neomycin (derivatives)with; Neomycin (derivatives)withbacitracin; Neomycin (derivativ... |
T36.6X5 | Adverse effect of rifampicins | Systemic antibiotics (T36) | Ansamycin; Rifabutin; Rifamide; Rifampicin; Rifampicinwith isoniazid; Rifampin; Rifamycin; Rifaximin |
T36.7X5 | Adverse effect of antifungal antibiotics, systemically used | Systemic antibiotics (T36) | Amphotericin B; Amphotericin Btopical; Antifungal; Antifungalantibiotic (systemic); Antifungalanti-infective NEC; Antifungaldisinfectant, local; Antifungalnonmedicinal (spray); Antifungaltopical; Fulvicin; Fungizone; Fungizonetopical; Grifulvin; Griseofulvin; Hachimycin; Mepartricin; Mycostatin; Mycostatintopical; Nilstat; Nilstattopical; Nystatin; Nystatintopical; Pimaricin; Trichomycin |
T36.8X5 | Adverse effect of other systemic antibiotics | Systemic antibiotics (T36) | Aerosporin; AerosporinENT agent; Aerosporinophthalmic preparation; Aerosporintopical NEC; Albamycin; Amfomycin; Amphomycin; Betamicin; Capreomycin; Carbomycin; Cathomycin; Ciprofloxacin; Clindamycin; Colimycin; Colistimethate; Colistin; Colistinsulfate (eye preparation); Co-trimoxazole; Enoxacin; Enviomycin; Fleroxacin; Fosfomycin; Fugillin; Fumadil; Fumagillin; Fusafungine; Fusidate (ethanolamine... |
T36.95 | Adverse effect of unspecified systemic antibiotic | Systemic antibiotics (T36) | Antibiotic NEC; Antibiotic NECaminoglycoside; Antibiotic NECanticancer; Antibiotic NECantifungal; Antibiotic NECantimycobacterial; Antibiotic NECantineoplastic; Antibiotic NECcephalosporin (group); Antibiotic NECchloramphenicol (group); Antibiotic NECENT; Antibiotic NECeye; Antibiotic NECfungicidal (local); Antibiotic NECintestinal; Antibiotic NECb-lactam NEC; Antibiotic NEClocal; Antibiotic NECma... |
T37.0X5 | Adverse effect of sulfonamides | Other systemic anti-infectives and antiparasitics (T37) | Acedapsone; Acesulfamethoxypyridazine; Acetylsulfamethoxypyridazine; Azosulfamide; Azulfidine; Diaphenylsulfone; Disulfanilamide; Neoprontosil; Phthalylsulfathiazole; Prontosil; Salazosulfapyridine; Salicylazosulfapyridine; Succinylsulfathiazole; Sulfachlorpyridazine; Sulfacitine; Sulfadiasulfone sodium; Sulfadiazine; Sulfadiazinesilver (topical); Sulfadimethoxine; Sulfadimidine; Sulfadoxine; Sulf... |
T37.1X5 | Adverse effect of antimycobacterial drugs | Other systemic anti-infectives and antiparasitics (T37) | Acetosulfone (sodium); Aldesulfone sodium; Aminosalicylic acid; Aminosalylum; Antimycobacterial drug NEC; Antimycobacterial drug NECantibiotics; Antimycobacterial drug NECcombination; Antituberculars; Antitubercularsantibiotics; Avlosulfon; Benzamidosalicylate (calcium); Benzoylpas calcium; Bromosalicylhydroxamic acid; Chaulmosulfone; Clofazimine; Cyanacetyl hydrazide; Cycloserine; DADPS; Dapsone;... |
T37.2X5 | Adverse effect of antimalarials and drugs acting on other blood protozoa | Other systemic anti-infectives and antiparasitics (T37) | 8-Aminoquinoline drugs; Amodiaquine; Amopyroquin (e); Antimalarial; Antimalarialprophylactic NEC; Antimalarialpyrimidine derivative; Aralen; Camoquin; Chloroguanide; Chloroquine; Chlorproguanil; Cinchona; Cinchonine alkaloids; Cycloguanil embonate; Daraprim; Eflornithine; Guanatol; Halofantrine; Isopentaquine; Mefloquine; Mepacrine; Paludrine; Pamaquine (naphthoute); Pentaquine; Primaquine; Progua... |
T37.3X5 | Adverse effect of other antiprotozoal drugs | Other systemic anti-infectives and antiparasitics (T37) | Acetarsol; Acterol; Aminitrozole; Antiprotozoal drug NEC; Antiprotozoal drug NECblood; Antiprotozoal drug NEClocal; Antitrichomonal drug; Arsthinol; Azanidazole; Benznidazole; Bialamicol; Carbarsone; Clefamide; Dehydroemetine; DHE; DHE45; Difetarsone; Diloxanide; Emetine; Etofamide; Flagyl; Glaucarubin; Glycobiarsol; Hydroxystilbamidine; Melarsonyl potassium; Melarsoprol; Misonidazole; Nifurtimox;... |
T37.4X5 | Adverse effect of anthelminthics | Other systemic anti-infectives and antiparasitics (T37) | Alantolactone; Albendazole; Amphotalide; Anthelmintic NEC; Anthiolimine; Antifilarial drug; Antihelmintics; Antihookworm drug; Antinematode drug; Antiplatyhelmintic drug; Antischistosomal drug; Antitapeworm drug; Antiwhipworm drug; Ascaridole; Aspidium (oleoresin); Bephenium hydroxy-naphthoate; Bitoscanate; Chenopodium; Dichlorophen; Diethylcarbamazine; Dithiazanine iodide; Fenbendazole; Filix mas... |
T37.5X5 | Adverse effect of antiviral drugs | Other systemic anti-infectives and antiparasitics (T37) | ABOB; Aciclovir; Acyclovir; Antiviral drug NEC; Antiviral drug NECeye; Ara-A; Azidothymidine; AZT; Dideoxycytidine; Dideoxyinosine; Flumidin; Foscarnet sodium; Fosfonet sodium; Ganciclovir (sodium); Ibacitabine; Inosine pranobex; Interferon (alpha) (beta) (gamma); Methisazone; Methisoprinol; Metisazone; Moroxydine; Ribavirin; Rimantadine; Thymopentin; Trifluridine; Tromantadine; Vidarabine; Virugo... |
T37.8X5 | Adverse effect of other specified systemic anti-infectives and antiparasitics | Other systemic anti-infectives and antiparasitics (T37) | Akritoin; Arsphenamine (silver); Bismarsen; Bithionol; Bithionolanthelminthic; Broxyquinoline; Chiniofon; Cinoxacin; Clioquinol; Croconazole; Dichlorhydroxyquinoline; Diiodohydroxyquin; Diiodohydroxyquintopical; Diiodohydroxyquinoline; Diodoquin; Floraquin; Fluconazole; Flucytosine; Flumequine; Flunidazole; Fluorocytosine; Furazolidone; Hexamine (mandelate); Hexetidine; Hydroxychloroquine; Hydroxy... |
T37.95 | Adverse effect of unspecified systemic anti-infective and antiparasitic | Other systemic anti-infectives and antiparasitics (T37) | Acriflavine; Anti-infective NEC; Anti-infective NECanthelmintic; Anti-infective NECantibiotics; Anti-infective NECantibioticsspecified NEC; Anti-infective NECantimalarial; Anti-infective NECantimycobacterial NEC; Anti-infective NECantimycobacterial NECantibiotics; Anti-infective NECantiprotozoal NEC; Anti-infective NECantiprotozoal NECblood; Anti-infective NECantiviral; Anti-infective NECarsenical... |
T38.0X5 | Adverse effect of glucocorticoids and synthetic analogues | Hormones and their synthetic substitutes and antag, NEC (T38) | Adrenal (extract, cortex or medulla) (glucocorticoids) (hormones) (mineralocorticoids); Adrenal (extract, cortex or medulla) (glucocorticoids) (hormones) (mineralocorticoids)ENT agent; Adrenal (extract, cortex or medulla) (glucocorticoids) (hormones) (mineralocorticoids)ophthalmic preparation; Adrenal (extract, cortex or medulla) (glucocorticoids) (hormones) (mineralocorticoids)topical NEC; Aristo... |
T38.1X5 | Adverse effect of thyroid hormones and substitutes | Hormones and their synthetic substitutes and antag, NEC (T38) | Cytomel; Detrothyronine; Dextrothyroxin; Dextrothyroxine sodium; Euthroid; I-thyroxine sodium; Letter; Levoid; Levothyroxine; Levothyroxinesodium; Liothyronine; Liotrix; Proloid; Synthroid; Thyroglobulin; Thyroid (hormone); Thyrolar; Thyroxine; Tiratricol; Titroid; Triiodothyronine |
T38.2X5 | Adverse effect of antithyroid drugs | Hormones and their synthetic substitutes and antag, NEC (T38) | Antithyroid drug NEC; Benzylthiouracil; Carbimazole; Diiodotyrosine; Iothiouracil; Methiacil; Methimazole; Methylthiouracil; Propylthiouracil; Tapazole; Thiamazole; Thiocarbamide; Thiouracil (benzyl) (methyl) (propyl); Thiourea |
T38.3X5 | Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs | Hormones and their synthetic substitutes and antag, NEC (T38) | Acetohexamide; Antidiabetic NEC; Antidiabetic NECbiguanide; Antidiabetic NECbiguanideand sulfonyl combined; Antidiabetic NECcombined; Antidiabetic NECsulfonylurea; Biguanide derivatives, oral; Buformin; Carbutamide; Chlorpropamide; DBI; Diabinese; Dymelor; Extended insulin zinc suspension; Glibenclamide; Glibornuride; Gliclazide; Glimidine; Glipizide; Gliquidone; Glisolamide; Glisoxepide; Globin z... |
T38.4X5 | Adverse effect of oral contraceptives | Hormones and their synthetic substitutes and antag, NEC (T38) | Antifertility pill; Contraceptive (oral); Contraceptive (oral)vaginal; Demulen; Enovid; Ethynodiol; Ethynodiolwith mestranol diacetate; Etinodiol; Etynodiol; Levonorgestrel; Levonorgestrelwith ethinylestradiol; Lynestrenol; Norethindrone; Norethisterone (acetate) (enantate); Norethisterone (acetate) (enantate)with ethinylestradiol; Norgestrel; Norgestrienone; Norlestrin; Norlutin; Oracon; Oral con... |
T38.5X5 | Adverse effect of other estrogens and progestogens | Hormones and their synthetic substitutes and antag, NEC (T38) | Allylestrenol; Anhydrohydroxy-progesterone; Chlormadinone; Chlorotrianisene; Chlortrianisene; Clomifene; Clomiphene; Conjugated estrogenic substances; Delalutin; Demegestone; Desogestrel; Diaethylstilboestrolum; Dienestrol; Dienoestrol; Diethylstilbestrol; Diethylstilboestrol; Dimestrol; Dimethisterone; Dydrogesterone; Epiestriol; Epimestrol; Estradiol; Estradiolwith testosterone; Estradiolbenzoat... |
T38.6X5 | Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified | Hormones and their synthetic substitutes and antag, NEC (T38) | Antiandrogen NEC; Antiestrogen NEC; Antigonadotrophin NEC; Cyproterone; Danazol; Flutamide; Mifepristone; Nafoxidine; Nilutamide; Ormeloxifene; Taleranol; Tamoxifen; Toremifene |
T38.7X5 | Adverse effect of androgens and anabolic congeners | Hormones and their synthetic substitutes and antag, NEC (T38) | Anabolic steroid; Androgen; Androgen-estrogen mixture; Androstalone; Androstanolone; Androsterone; Calusterone; Chlorodehydro-methyltestosterone; Congener, anabolic; Dromostanolone; Drostanolone; Durabolin; Epitiostanol; Estanozolol; Ethylestrenol; Fluoxymesterone; Macrolide; Macrolideanabolic drug; Macrolideantibiotic; Mepitiostane; Mestanolone; Mesterolone; Metandienone; Metandrostenolone; Meten... |
T38.805 | Adverse effect of unspecified hormones and synthetic substitutes | Hormones and their synthetic substitutes and antag, NEC (T38) | Hormone; Hormoneadrenal cortical steroids; Hormoneandrogenic; Hormoneanterior pituitary NEC; Hormoneantidiabetic agents; Hormoneantidiuretic; Hormonecancer therapy; Hormonefollicle stimulating; Hormonegonadotropic; Hormonegonadotropicpituitary; Hormonegrowth; Hormoneluteinizing; Hormoneovarian; Hormoneoxytocic; Hormoneparathyroid (derivatives); Hormonepituitary (posterior) NEC; Hormonepituitary (p... |
T38.815 | Adverse effect of anterior pituitary [adenohypophyseal] hormones | Hormones and their synthetic substitutes and antag, NEC (T38) | ACTH; Adrenocorticotrophic hormone; Adrenocorticotrophin; Alsactide; Anterior pituitary hormone NEC; Corticotropin; Cosyntropin; Follicle-stimulating hormone, human; FSH; Growth hormone; HGH (human growth hormone); Luteinizing hormone; Menotropins; Pergonal; Prolactin; Seractide; Somatotropin; Somatrem; Somatropin; Tetracosactide; Tetracosactrin; Thyreotrophic hormone; Thyrotrophin; Thyrotropic ho... |
T38.895 | Adverse effect of other hormones and synthetic substitutes | Hormones and their synthetic substitutes and antag, NEC (T38) | ADH; Antidiuretic hormone; Buserelin; Chorionic gonadotropin; DDAVP; Deamino-D-arginine vasopressin; Desmopressin; Enterogastrone; Felypressin; Gonadorelin; Gonadotropin; Gonadotropinchorionic; Gonadotropinpituitary; Hypophysis, posterior; Leuprolide; Lypressin; Lysine vasopressin; Melanocyte-stimulating hormone; Pitressin (tannate); Pituitary extracts (posterior); Pituitary extracts (posterior)an... |
T38.905 | Adverse effect of unspecified hormone antagonists | Hormones and their synthetic substitutes and antag, NEC (T38) | Gonadal tissue extract; Gonadal tissue extractfemale; Gonadal tissue extractmale |
T38.995 | Adverse effect of other hormone antagonists | Hormones and their synthetic substitutes and antag, NEC (T38) | Octreotide; Somatostatin; Trilostane |
T39.015 | Adverse effect of aspirin | Nonopioid analgesics, antipyretics and antirheumatics (T39) | Acetylsalicylic acid (salts); Acetylsalicylic acid (salts)enteric coated; Alka-seltzer; Aspirin (aluminum) (soluble); Bufferin; Carbaspirin; Fiorinal; Rhodine |
T39.095 | Adverse effect of salicylates | Nonopioid analgesics, antipyretics and antirheumatics (T39) | Carbethyl salicylate; Diflunisal; Salicylamide; Salicylate NEC; Salicylate NECmethyl; Salicylate NECtheobromine calcium; Salsalate |
T39.1X5 | Adverse effect of 4-Aminophenol derivatives | Nonopioid analgesics, antipyretics and antirheumatics (T39) | P-Acetamidophenol; Acetaminophen; Acetaminosalol; Acetanilide; Acetophenetedin; 4-Aminophenol derivatives; Bromo-seltzer; Exalgin; Panadol; Para-acetamidophenol; Para-aminophenol derivatives; Paracetamol; Phenacetin |
T39.2X5 | Adverse effect of pyrazolone derivatives | Nonopioid analgesics, antipyretics and antirheumatics (T39) | Amidopyrine; Aminofenazone; Aminophenazone; Aminopyrine; Analgin; Antipyrine; Azapropazone; Butazolidin; Clofezone; Diphenylbutazone; Dipyrone; Fenazone; Fenylbutazone; Feprazone; Hydroxyphenylbutazone; Indocin; Isopropylaminophenazone; Kebuzone; Ketazon; Metamizole sodium; Methampyrone; Mofebutazone; Monophenylbutazone; Myochrysin (e); Nifenazone; Noramidopyrine; Noramidopyrinemethanesulfonate so... |
T39.315 | Adverse effect of propionic acid derivatives | Nonopioid analgesics, antipyretics and antirheumatics (T39) | Carprofen; Esflurbiprofen; Fenoprofen; Flurbiprofen; Ibufenac; Ibuprofen; Ibuproxam; Ketoprofen; Naproxen; Oxaprozin; Suprofen; Tiaprofenic acid |
T39.395 | Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID] | Nonopioid analgesics, antipyretics and antirheumatics (T39) | Anti-inflammatory drug NEC; Anti-inflammatory drug NEClocal; Anti-inflammatory drug NECnonsteroidal NEC; Anti-inflammatory drug NECnonsteroidal NECpropionic acid derivative; Anti-inflammatory drug NECspecified NEC; Diclofenac; Etodolac; Fenflumizole; Flufenamic acid; Indometacin; Indomethacin; Indomethacinfarnesil; Isoxicam; Meclofenamate; Meclofenamic acid; Mefenamic acid; Nabumetone; Nimesulide;... |
T39.4X5 | Adverse effect of antirheumatics, not elsewhere classified | Nonopioid analgesics, antipyretics and antirheumatics (T39) | Antiphlogistic NEC; Antirheumatic NEC; Auranofin; Aurothioglucose; Aurothioglycanide; Aurothiomalate sodium; Aurotioprol; Glucosamine sulfate |
T39.8X5 | Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified | Nonopioid analgesics, antipyretics and antirheumatics (T39) | Acetylphenylhydrazine; Carbiphene; Clonixin; Cropropamide; Cropropamidewith crotethamide; Crotethamide; Crotethamidewith cropropamide; Cryogenine; Cyclopyrabital; Darvon; Diclonixine; Doloxene; Emorfazone; Etomide; Floctafenine; Fluradoline; Glafenine; Jamaica; Jamaicadogwood (bark); Jamaicaginger; Jamaicagingerroot; Ketorolac; Lefetamine; Meptazinol; Methopholine; Metofoline; Nefopam; Oxetorone; ... |
T39.95 | Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic | Nonopioid analgesics, antipyretics and antirheumatics (T39) | Analgesic; Analgesicanti-inflammatory NEC; Analgesicanti-inflammatory NECpropionic acid derivative; Analgesicantirheumatic NEC; Analgesicaromatic NEC; Analgesicnarcotic NEC; Analgesicnarcotic NECcombination; Analgesicnarcotic NECobstetric; Analgesicnon-narcotic NEC; Analgesicnon-narcotic NECcombination; Analgesicpyrazole; Analgesicspecified NEC; Antipyretic; Antipyreticspecified NEC |
T40.0X5 | Adverse effect of opium | Narcotics and psychodysleptics (T40) | Laudanum; Opium alkaloids (total); Opium alkaloids (total)standardized powdered; Opium alkaloids (total)tincture (camphorated); Pantopon; Papaveretum; Paregoric |
T40.2X5 | Adverse effect of other opioids | Narcotics and psychodysleptics (T40) | 14-hydroxydihydro-morphinone; Acemorphan; Alvodine; Benzomorphan; Codeine; Demerol; Desocodeine; Dextrorphan; Difencloxazine; Dihydrocodeine; Dihydrocodeinone; Dihydrohydroxycodeinone; Dihydrohydroxymorphinone; Dihydroisocodeine; Dihydromorphinone; Dihydroxycodeinone; Dilaudid; Dionin; Drocode; Dromoran; Ethylmorphine; Etorphine; Eucodal; Heptalgin; Hycodan; Hydrocodone; Hydromorphinone; Hydromorp... |
T40.3X5 | Adverse effect of methadone | Narcotics and psychodysleptics (T40) | Amidone; Dolophine; Levo-iso-methadone; Methadone; Physeptone |
T40.415 | Adverse effect of fentanyl or fentanyl analogs | Narcotics and psychodysleptics (T40) | Alfentanil; Fentanyl (analogs); Sufentanil |
T40.425 | Adverse effect of tramadol | Narcotics and psychodysleptics (T40) | Tramadol |
T40.495 | Adverse effect of other synthetic narcotics | Narcotics and psychodysleptics (T40) | Alphaprodine; Anileridine; Bezitramide; Buprenorphine; Butorphanol; Dextropropoxyphene; Eptazocine; Ethoheptazine; Isonipecaine; Levopropoxyphene; Levorphanol; Meperidine; Nalbuphine; Pentazocine; Pethidine; Phenazocine; Profadol; Propoxyphene |
T40.5X5 | Adverse effect of cocaine | Narcotics and psychodysleptics (T40) | Coca (leaf); Cocaine; Cocainetopical anesthetic |
T40.605 | Adverse effect of unspecified narcotics | Narcotics and psychodysleptics (T40) | Narcotic (drug); Narcotic (drug)analgesic NEC; Narcotic (drug)antagonist; Narcotic (drug)specified NEC; Narcotic (drug)synthetic; Opiate NEC; Opiate NECantagonists |
T40.715 | Adverse effect of cannabis | Narcotics and psychodysleptics (T40) | Afghanistan black; Bhang; Cannabinol; Cannabis (derivatives); Dronabinol; Ganja; Hashish; Indian; Indianhemp; Indiantobacco; Lebanese red; Marihuana; Marijuana; Nabilone; Pot; Tetrahydrocannabinol; THC |
T40.725 | Adverse effect of synthetic cannabinoids | Narcotics and psychodysleptics (T40) | Cannabinoids, synthetic; Synthetic cannabinoids |
T40.905 | Adverse effect of unspecified psychodysleptics [hallucinogens] | Narcotics and psychodysleptics (T40) | Hallucinogen NOS; Hallucinogen NOSspecified NEC; Megahallucinogen; Psychodysleptic drug NOS; Psychodysleptic drug NOSspecified NEC; Psychotomimetic agents |
T40.995 | Adverse effect of other psychodysleptics [hallucinogens] | Narcotics and psychodysleptics (T40) | Phencyclidine; Yohimbic acid |
T41.0X5 | Adverse effect of inhaled anesthetics | Anesthetics and therapeutic gases (T41) | Divinyl ether; Enflurane; Ether (vapor); Ether (vapor)anesthetic; Ether (vapor)divinyl; Ether (vapor)ethyl (medicinal); Ether (vapor)ethyl (medicinal)nonmedicinal; Ether (vapor)petroleum; Ether (vapor)solvent; Fluothane; Fluroxene; Halothane; Isoflurane; Laughing gas; Methoxyflurane; Trifluoroethyl vinyl ether; Trilene; Vinesthene, vinethene |
T41.1X5 | Adverse effect of intravenous anesthetics | Anesthetics and therapeutic gases (T41) | Alfadolone; Alfaxalone; Alphadolone; Alphaxalone; Brevital (sodium); Buthalitone (sodium); Etomidate; Intranarcon; Kemithal; Methohexital; Methohexitone; Pentothal; Sernyl; Surital; Thialbarbital; Thiamylal; Thiamylalsodium; Thiobarbital sodium; Thiobarbiturate anesthetic; Thiobutabarbital sodium; Thiopental (sodium); Thiopentone (sodium) |
T41.205 | Adverse effect of unspecified general anesthetics | Anesthetics and therapeutic gases (T41) | Premedication anesthetic |
T41.295 | Adverse effect of other general anesthetics | Anesthetics and therapeutic gases (T41) | Cyclopropane; Disoprofol; Ketamine; Minaxolone; Oxybate sodium; Propanidid; Propofol; Tiletamine; Tribromoethanol, rectal |
T41.3X5 | Adverse effect of local anesthetics | Anesthetics and therapeutic gases (T41) | Amethocaine; Amethocaineregional; Amethocainespinal; Amyleine, regional; Amylocaine, regional; Amylocaine, regionalinfiltration (subcutaneous); Amylocaine, regionalnerve block (peripheral) (plexus); Amylocaine, regionalspinal; Amylocaine, regionaltopical (surface); Anesthesia; Anesthesiacaudal; Anesthesiaendotracheal; Anesthesiaepidural; Anesthesiainhalation; Anesthesialocal; Anesthesiamucosal; An... |
T41.45 | Adverse effect of unspecified anesthetic | Anesthetics and therapeutic gases (T41) | Anesthetic NEC [See Also: Anesthesia]; Anesthetic NEC [See Also: Anesthesia]with muscle relaxant; Anesthetic NEC [See Also: Anesthesia]with muscle relaxantgeneral; Anesthetic NEC [See Also: Anesthesia]with muscle relaxantlocal; Anesthetic NEC [See Also: Anesthesia]gaseous NEC; Anesthetic NEC [See Also: Anesthesia]general NEC; Anesthetic NEC [See Also: Anesthesia]halogenated hydrocarbon derivatives... |
T41.5X5 | Adverse effect of therapeutic gases | Anesthetics and therapeutic gases (T41) | Oxygen |
T42.0X5 | Adverse effect of hydantoin derivatives | Antiepileptic, sedative- hypnotic and antiparkinsonism drugs (T42) | Albutoin; Dilantin; Diphenylhydantoin; Epanutin; Ethotoin; Hydantoin derivative NEC; Mephenytoin; Mephenytoinwith phenobarbital; Metetoin; Methetoin; Methoin; Phenantoin; Phenytoin; Phenytoinwith Phenobarbital |
T42.1X5 | Adverse effect of iminostilbenes | Antiepileptic, sedative- hypnotic and antiparkinsonism drugs (T42) | Carbamazepine; Iminostilbene; Oxcarbazepine; Tegretol |
T42.2X5 | Adverse effect of succinimides and oxazolidinediones | Antiepileptic, sedative- hypnotic and antiparkinsonism drugs (T42) | Aloxidone; Ethadione; Ethosuximide; Isoethadione; Mesuximide; Methsuximide; Morsuximide; Oxazolidine derivatives; Oxazolidinedione (derivative); Paradione; Paramethadione; Phensuximide; Succinimide, antiepileptic or anticonvulsant; Succinimide, antiepileptic or anticonvulsantmercuric; Tridione; Trimethadione; Troxidone |
T42.3X5 | Adverse effect of barbiturates | Antiepileptic, sedative- hypnotic and antiparkinsonism drugs (T42) | Agrypnal; Allobarbital; Allylisopropylmalonylurea; Allypropymal; Alurate; Amobarbital (sodium); Amylobarbitone; Amytal (sodium); Aprobarbital; Barbenyl; Barbital; Barbitalsodium; Barbitone; Barbiturate NEC; Barbiturate NECwith tranquilizer; Barbiturate NECanesthetic (intravenous); Brallobarbital; Butabarbital (sodium); Butabarbitone; Butabarpal; Butalbital; Butallylonal; Butethal; Butisol (sodium)... |
T42.4X5 | Adverse effect of benzodiazepines | Antiepileptic, sedative- hypnotic and antiparkinsonism drugs (T42) | Alprazolam; Bentazepam; Benzodiapin; Benzodiazepine NEC; Bromazepam; Brotizolam; Camazepam; Carpipramine; Chlordiazepoxide; Clobazam; Clonazepam; Clorazepate (dipotassium); Clotiazepam; Cloxazolam; Clozapine; Dalmane; Delorazepam; Diazepam; Estazolam; Etizolam; Fludiazepam; Flunitrazepam; Flurazepam; Flutazolam; Flutoprazepam; Halazepam; Haloxazolam; Ketazolam; Librium; Loprazolam; Lorazepam; Lorm... |
T42.6X5 | Adverse effect of other antiepileptic and sedative-hypnotic drugs | Antiepileptic, sedative- hypnotic and antiparkinsonism drugs (T42) | Acecarbromal; Acetylcarbromal; Acetylpheneturide; Allylisopropylacetylurea; Allyltribromide; Apronalide; Avomine; Barbexaclone; Beclamide; Beta-Chlor; Bromal (hydrate); Bromide salts; Bromine; Brominecompounds (medicinal); Brominesedative; Brominevapor; Bromisoval; Bromisovalum; Bromoform; Bromural; Bromvaletone; Butylchloral hydrate; Carbamate (sedative); Carbamate (sedative)herbicide; Carbamate ... |
T42.75 | Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs | Antiepileptic, sedative- hypnotic and antiparkinsonism drugs (T42) | Anticonvulsant; Anticonvulsantbarbiturate; Anticonvulsantcombination (with barbiturate); Anticonvulsanthydantoin; Anticonvulsanthypnotic NEC; Anticonvulsantoxazolidinedione; Anticonvulsantpyrimidinedione; Anticonvulsantspecified NEC; Anticonvulsantsuccinimide; Antiepilepsy agent; Antiepilepsy agentcombination; Antiepilepsy agentmixed; Antiepilepsy agentspecified, NEC; Central nervous system; Centr... |
T42.8X5 | Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants | Antiepileptic, sedative- hypnotic and antiparkinsonism drugs (T42) | Afloqualone; Amantadine; Antiparkinsonism drug NEC; Antirigidity drug NEC; Baclofen; Benserazide; Benzatropine; Bromocriptine; Cabergoline; Carbidopa (with levodopa); Carisoprodol; Chlorphenesin; Chlorphenesintopical (antifungal); Chlorzoxazone; Dantrolene; Deprenalin; Deprenyl; Diethazine; Difluoromethyldopa; Disipal; Dopa; Idrocilamide; L-dopa; Levodopa; Levodopawith carbidopa; Lisuride; Mephena... |
T43.015 | Adverse effect of tricyclic antidepressants | Psychotropic drugs, not elsewhere classified (T43) | Allegron; Amineptine; Amitriptyline; Amitriptylinoxide; Amoxapine; Butriptyline; Chlorimipramine; Cianopramine; Clomipramine; Desipramine; Desmethylimipramine; Dibenzepin; Dosulepin; Dothiepin; Doxepin; Imipramine; Iprindole; Laroxyl; Lofepramine; Melitracen; Metapramine; Nortriptyline; Noxiptiline; Opipramol; Pertofrane; Protriptyline; Quinupramine; Saroten; Sinequan; Tofranil; Trimipramine; Tryp... |
T43.025 | Adverse effect of tetracyclic antidepressants | Psychotropic drugs, not elsewhere classified (T43) | Maprotiline; Mianserin; Mirtazapine; Oxaprotiline |
T43.1X5 | Adverse effect of monoamine-oxidase-inhibitor antidepressants | Psychotropic drugs, not elsewhere classified (T43) | Amiflamine; Clorgiline; Iproclozide; Iproniazid; Isocarboxazid; MAO inhibitors; Marplan; Marsilid; Mebanazine; Moclobemide; Monoamine oxidase inhibitor NEC; Monoamine oxidase inhibitor NEChydrazine; Nardil; Nialamide; Parnate; Phenelzine; Pheniprazine; Safrazine; Tranylcypromine |
T43.205 | Adverse effect of unspecified antidepressants | Psychotropic drugs, not elsewhere classified (T43) | Antidepressant; Antidepressantmonoamine oxidase inhibitor; Antidepressantselective serotonin norepinephrine reuptake inhibitor; Antidepressantselective serotonin reuptake inhibitor; Antidepressantspecified NEC; Antidepressanttetracyclic; Antidepressanttriazolopyridine; Antidepressanttricyclic |
T43.215 | Adverse effect of selective serotonin and norepinephrine reuptake inhibitors | Psychotropic drugs, not elsewhere classified (T43) | Trazodone; Venlafaxine |
T43.225 | Adverse effect of selective serotonin reuptake inhibitors | Psychotropic drugs, not elsewhere classified (T43) | Citalopram; Femoxetine; Fluoxetine; Fluvoxamine; Indalpine; Zimeldine |
T43.295 | Adverse effect of other antidepressants | Psychotropic drugs, not elsewhere classified (T43) | Amfebutamone; Bifemelane; Bupropion; Diclofensine; Minaprine; Nomifensine; Oxitriptan; Prazitone; Thiazesim; Tianeptine; Viloxazine |
T43.3X5 | Adverse effect of phenothiazine antipsychotics and neuroleptics | Psychotropic drugs, not elsewhere classified (T43) | Acepromazine; Acetophenazine; Alimemazine; Butaperazine; Carfenazine; Carphenazine; Chlorpromazine; Compazine; Cyamemazine; Dimetotiazine; Dioxopromethazine; Dixyrazine; Fentazin; Fluopromazine; Fluphenazine; Isopromethazine; Largactil; Levomepromazine; Levopromazine; Mellaril; Mepazine; Mequitazine; Mesoridazine; Methdilazine; Methopromazine; Methotrimeprazine; Methoxypromazine; Metofenazate; Oxo... |
T43.4X5 | Adverse effect of butyrophenone and thiothixene neuroleptics | Psychotropic drugs, not elsewhere classified (T43) | Benperidol; Bromperidol; Butyrophenone (-based tranquilizers); Chlorprothixene; Clopenthixol; Fluanisone; Flupenthixol; Flupentixol; Haloperidol; Lenperone; Melperone; Moperone; Pipamperone; Spiperone; Spiroperidol; Thiothixene; Timiperone; Tiotixene; Trifluperidol; Triperidol; Zuclopenthixol |
T43.505 | Adverse effect of unspecified antipsychotics and neuroleptics | Psychotropic drugs, not elsewhere classified (T43) | Antianxiety drug NEC; Antihallucinogen; Antipsychotic drug; Antipsychotic drugspecified NEC; Ataractic drug NEC; Neuroleptic drug NEC; Tranquilizer NEC; Tranquilizer NECwith hypnotic or sedative; Tranquilizer NECbenzodiazepine NEC; Tranquilizer NECbutyrophenone NEC; Tranquilizer NECcarbamate; Tranquilizer NECdimethylamine; Tranquilizer NECethylamine; Tranquilizer NEChydroxyzine; Tranquilizer NECma... |
T43.595 | Adverse effect of other antipsychotics and neuroleptics | Psychotropic drugs, not elsewhere classified (T43) | Aminophenylpyridone; Amisulpride; Amperozide; Amphenidone; Azacyclonol; Benzperidin; Benzperidol; Buspirone; Captodiame, captodiamine; Clotiapine; Droperidol; Emylcamate; Enpiprazole; Equanil; Fluspirilene; Hydroxyphenamate; Hydroxyzine; Loxapine; Mebutamate; Meprobam; Meprobamate; Miltown; Molindone; Mosapramine; Nemonapride; Olanzapine; Oxanamide; Oxypertine; Penfluridol; Phenaglycodol; Pimozide... |
T43.605 | Adverse effect of unspecified psychostimulants | Psychotropic drugs, not elsewhere classified (T43) | Cerebral stimulants; Cerebral stimulantspsychotherapeutic; Cerebral stimulantsspecified NEC; Psychostimulant; Psychostimulantamphetamine; Psychostimulantcaffeine; Psychostimulantmethylphenidate; Psychostimulantspecified NEC; Stimulant; Stimulantcentral nervous system [See Also: Psychostimulant]; Stimulantcentral nervous system [See Also: Psychostimulant]analeptics; Stimulantcentral nervous system ... |
T43.615 | Adverse effect of caffeine | Psychotropic drugs, not elsewhere classified (T43) | Caffeine |
T43.625 | Adverse effect of amphetamines | Psychotropic drugs, not elsewhere classified (T43) | Amfetamine; Amfetaminil; Amphetamine NEC; Benzedrine (amphetamine); Dexamfetamine; Dexamphetamine; Dexedrine; Dextroamphetamine; Methylenedioxyamphetamine; Tenamfetamine |
T43.635 | Adverse effect of methylphenidate | Psychotropic drugs, not elsewhere classified (T43) | Methylphenidate; Ritalin |
T43.695 | Adverse effect of other psychostimulants | Psychotropic drugs, not elsewhere classified (T43) | Etryptamine; Fencamfamine; Fenetylline; Meclofenoxate; Pipradrol; Preludin; Prolintane |
T43.8X5 | Adverse effect of other psychotropic drugs | Psychotropic drugs, not elsewhere classified (T43) | 4-Aminobutyric acid; Eskalith; GABA; Gamma-aminobutyric acid; Lithane; Lithonate; Memantine; Namenda; Nizofenone |
T43.95 | Adverse effect of unspecified psychotropic drug | Psychotropic drugs, not elsewhere classified (T43) | Psychotherapeutic drug NEC; Psychotherapeutic drug NECantidepressants [See Also: Antidepressant]; Psychotherapeutic drug NECspecified NEC; Psychotherapeutic drug NECtranquilizers NEC; Psychotropic drug NEC; Psychotropic drug NECspecified NEC |
T44.0X5 | Adverse effect of anticholinesterase agents | Drugs primarily affecting the autonomic nervous system (T44) | Ambenonium (chloride); Anticholinesterase; Anticholinesteraseorganophosphorus; Anticholinesteraseorganophosphorusinsecticide; Anticholinesteraseorganophosphorusnerve gas; Anticholinesterasereversible; Anticholinesterasereversibleophthalmological; DFP; Diflos; Difluorophate; Diisopropylfluorophos-phonate; Distigmine (bromide); Dyflos; Edrophonium; Edrophoniumchloride; Galantamine; Isoflurophate; Ne... |
T44.1X5 | Adverse effect of other parasympathomimetics [cholinergics] | Drugs primarily affecting the autonomic nervous system (T44) | Aceclidine; Acetylcholine; Acetylcholinechloride; Acetylcholinederivative; Arecoline; Benzpyrinium bromide; Bethanechol; Bethanecholchloride; Carbachol; Carbamylcholine chloride; Cholinergic (drug) NEC; Cholinergic (drug) NECmuscle tone enhancer; Cholinergic (drug) NECorganophosphorus; Cholinergic (drug) NECorganophosphorusinsecticide; Cholinergic (drug) NECorganophosphorusnerve gas; Cholinergic (... |
T44.2X5 | Adverse effect of ganglionic blocking drugs | Drugs primarily affecting the autonomic nervous system (T44) | Ganglionic blocking drug NEC; Ganglionic blocking drug NECspecified NEC; Hexamethonium bromide; Mecamylamine; Pempidine; Pentamethonium bromide; Pentapyrrolinium (bitartrate); Pentolonium tartrate; Tetraethylammonium chloride; Tetrylammonium chloride; Trimetaphan camsilate; Trimethaphan; Trimethidinium |
T44.3X5 | Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics | Drugs primarily affecting the autonomic nervous system (T44) | Adiphenine; Alverine; Ambutonium bromide; Aminopentamide; Amprotropine; Aniscoropine; Anisotropine methyl-bromide; Anticholinergic NEC; Antimuscarinic NEC; Artane; Atropine; Atropinederivative; Atropinemethonitrate; Belladonna [See Also: Nightshade]; Belladonna [See Also: Nightshade]alkaloids; Belladonna [See Also: Nightshade]extract; Belladonna [See Also: Nightshade]herb; Benactyzine; Benaprizine... |
T44.4X5 | Adverse effect of predominantly alpha-adrenoreceptor agonists | Drugs primarily affecting the autonomic nervous system (T44) | Agonist; Agonistpredominantly; Agonistpredominantlyalpha-adrenoreceptor; Agonistpredominantlybeta-adrenoreceptor; Aplonidine; Apraclonidine (hydrochloride); Cyclopentamine; Etilefrine; Gepefrine; Levarterenol; Metaraminol; Methoxamine; Noradrenaline; Norepinephrine; Norfenefrine; Oxedrine; Paredrine; Phenylephrine; Privine |
T44.5X5 | Adverse effect of predominantly beta-adrenoreceptor agonists | Drugs primarily affecting the autonomic nervous system (T44) | Adrenaline; Angiotensin; Beclomethasone; Budesonide; Dobutamine; Epinephrine; Isoetharine; Prenalterol; Procaterol; Racepinefrin; Ritodrine; Xamoterol |
T44.6X5 | Adverse effect of alpha-adrenoreceptor antagonists | Drugs primarily affecting the autonomic nervous system (T44) | Bunazosin; Dibenamine; Dibenzyline; Doxazosin; Flomax; Hydergine; Indoramin; Prazosin; Priscol, Priscoline; Tamsulosin; Terazosin |
T44.7X5 | Adverse effect of beta-adrenoreceptor antagonists | Drugs primarily affecting the autonomic nervous system (T44) | Acebutolol; Alprenolol; Atenolol; beta adrenergic blocking agent, heart; Betaxolol; Bevantolol; Bisoprolol; Bopindolol; Bunitrolol; Bupranolol; Carazolol; Carteolol; Celiprolol; Esmolol; Indenolol; Inderal; Mepindolol; Metoprolol; Nadolol; Oxprenolol; Penbutolol; Pindolol; Practolol; Pronetalol; Propranolol; Sotalol; Tertatolol; Timolol; Tolamolol |
T44.8X5 | Adverse effect of centrally-acting and adrenergic-neuron-blocking agents | Drugs primarily affecting the autonomic nervous system (T44) | Alfuzosin (hydrochloride); Antiadrenergic NEC; Labetalol; Medroxalol; Sympatholytic NEC; Sympatholytic NEChaloalkylamine |
T44.905 | Adverse effect of unspecified drugs primarily affecting the autonomic nervous system | Drugs primarily affecting the autonomic nervous system (T44) | Adrenergic NEC; Adrenergic NECblocking agent NEC; Adrenergic NECblocking agent NECbeta, heart; Adrenergic NECspecified NEC; Autonomic nervous system agent NEC; Sympathomimetic NEC; Sympathomimetic NECanti-common-cold; Sympathomimetic NECbronchodilator; Sympathomimetic NECspecified NEC |
T44.995 | Adverse effect of other drug primarily affecting the autonomic nervous system | Drugs primarily affecting the autonomic nervous system (T44) | Amezinium metilsulfate; Angiotensinamide; Benzedrex; Dopamine; Ephedra; Ephedrine; Ibopamine; Isoephedrine; Mephentermine; Phenylpropanolamine; Pseudoephedrine |
T45.0X5 | Adverse effect of antiallergic and antiemetic drugs | Primarily systemic and hematological agents, NEC (T45) | Acrivastine; Alizapride; Antazolin (e); Antiallergic NEC; Antiemetic drug; Antihistamine; Antinausea drug; Antistine; Antivertigo drug; Astemizole; Azatadine; Azelastine; Bamipine; Benadryl; Benzhydramine (chloride); Benzquinamide; Bisulepin (hydrochloride); Bonine; Bromazine; Bromodiphenhydramine; Brompheniramine; Buclizine; Carbinoxamine; Cerium oxalate; Cerous oxalate; Cetirizine; Cetoxime; Chl... |
T45.1X5 | Adverse effect of antineoplastic and immunosuppressive drugs | Primarily systemic and hematological agents, NEC (T45) | Aclarubicin; Actinomycin C; Actinomycin D; Adriamycin; Alkylating drug NEC; Alkylating drug NECantimyeloproliferative; Alkylating drug NEClymphatic; Altretamine; Amethopterin; Aminoglutethimide; Aminopterin sodium; Amsacrine; Anthramycin; Anticancer agents NEC; Antimetabolite; Antimitotic agent; Antineoplastic NEC; Antineoplastic NECalkaloidal; Antineoplastic NECantibiotics; Antineoplastic NECcomb... |
T45.2X5 | Adverse effect of vitamins | Primarily systemic and hematological agents, NEC (T45) | Acetiamine; Adenine; Adeninearabinoside; Alfacalcidol; Aneurine; Ascorbic acid; Axerophthol; Benfotiamine; Betacarotene; Biotin; Bisbentiamine; Bisbutiamine; Calcifediol; Calciferol; Calcitriol; Carotene; Cetotiamine; Cevitamic acid; Cholecalciferol; Cobalamine; Cod-liver oil; Colecalciferol; Cozyme; Dexpanthenol; Dextro calcium pantothenate; Dextro pantothenyl alcohol; Dihydrotachysterol; Ergocal... |
T45.3X5 | Adverse effect of enzymes | Primarily systemic and hematological agents, NEC (T45) | Alglucerase; Alidase; Brinase; Bromelains; Catalase; Chymar; Chymarophthalmic preparation; Chymopapain; Chymotrypsin; Chymotrypsinophthalmic preparation; Cocarboxylase; Deoxyribonuclease (pancreatic); Diffusin; Enzodase; Enzyme NEC; Enzyme NECdepolymerizing; Enzyme NECfibrolytic; Enzyme NECgastric; Enzyme NECintestinal; Enzyme NEClocal action; Enzyme NECproteolytic; Enzyme NECthrombolytic; Hyaluro... |
T45.4X5 | Adverse effect of iron and its compounds | Primarily systemic and hematological agents, NEC (T45) | Dextriferron; Ferric [See Also: Iron]; Ferric [See Also: Iron]chloride; Ferric [See Also: Iron]citrate; Ferric [See Also: Iron]hydroxide; Ferric [See Also: Iron]hydroxidecolloidal; Ferric [See Also: Iron]hydroxidepolymaltose; Ferric [See Also: Iron]pyrophosphate; Ferritin; Ferrocholinate; Ferrodextrane; Ferropolimaler; Ferrous [See Also: Iron]; Ferrous [See Also: Iron]phosphate; Ferrous [See Also:... |
T45.515 | Adverse effect of anticoagulants | Primarily systemic and hematological agents, NEC (T45) | Acenocoumarin; Acenocoumarol; Anisindione; Anticoagulant NEC; Anticoagulant NECAntagonist; Bishydroxycoumarin; Bromindione; Coumadin; Coumadinrodenticide; Coumarin; Coumetarol; Cumetharol; Danilone; Dicoumarol, dicoumarin, dicumarol; Diphenadione; Diphenadionerodenticide; Drotrecogin alfa; Enoxaparin (sodium); Fluindione; Heparin (sodium); Heparin (sodium)action reverser; Heparin-fraction; Heparin... |
T45.525 | Adverse effect of antithrombotic drugs | Primarily systemic and hematological agents, NEC (T45) | Antithrombotic; Epoprostenol; Indobufen; Prostacyclin; Prostaglandin (I2); Prostaglandin (I2)E1; Prostaglandin (I2)E2; Prostaglandin (I2)F2 alpha; Ticlopidine; Triflusal |
T45.605 | Adverse effect of unspecified fibrinolysis-affecting drugs | Primarily systemic and hematological agents, NEC (T45) | Fibrinolysis; Fibrinolysisaffecting drug; Fibrinolysisinhibitor NEC |
T45.615 | Adverse effect of thrombolytic drugs | Primarily systemic and hematological agents, NEC (T45) | Alteplase; Anistreplase; Fibrinolytic drug; Plasminogen (tissue) activator; Rt-PA; Streptokinase; Thrombolysin; Urokinase |
T45.625 | Adverse effect of hemostatic drug | Primarily systemic and hematological agents, NEC (T45) | Aminocaproic acid; Antifibrinolytic drug; Aprotinin; Epsilon amino-caproic acid; Hemostatic; Hemostaticdrug, systemic; Tranexamic acid |
T45.695 | Adverse effect of other fibrinolysis-affecting drugs | Primarily systemic and hematological agents, NEC (T45) | Aminomethylbenzoic acid; Ancrod; Fibrinolysin (human) |
T45.7X5 | Adverse effect of anticoagulant antagonists, vitamin K and other coagulants | Primarily systemic and hematological agents, NEC (T45) | Acetomenaphthone; Antiheparin drug; Coagulant NEC; Cotarnine; Cytozyme; Etamsylate; Ethamsylate; Gelfoam; Hexadimethrine (bromide); Menadiol; Menadiolsodium sulfate; Menadione; Menadionesodium bisulfite; Menaphthone; Menaquinone; Menatetrenone; Phylloquinone; Phytomenadione; Phytonadione; Protamine sulfate; Protamine sulfatezinc insulin; Prothrombin; Prothrombinactivator; Prothrombinsynthesis inhi... |
T45.8X5 | Adverse effect of other primarily systemic and hematological agents | Primarily systemic and hematological agents, NEC (T45) | Albumin; Albuminbovine; Albuminhuman serum; Albuminhuman serumsalt-poor; Albuminnormal human serum; Aminoethylisothiourium; Anti-anemic (drug) (preparation); Antihemophilic; Antihemophilicfactor; Antihemophilicfraction; Antihemophilicglobulin concentrate; Antihemophilichuman plasma; Antihemophilicplasma, dried; BAL; Blood (derivatives) (natural) (plasma) (whole); Blood (derivatives) (natural) (pla... |
T45.95 | Adverse effect of unspecified primarily systemic and hematological agent | Primarily systemic and hematological agents, NEC (T45) | Hematological agent; Hematological agentspecified NEC; Systemic drug; Systemic drugspecified NEC |
T46.0X5 | Adverse effect of cardiac-stimulant glycosides and drugs of similar action | Agents primarily affecting the cardiovascular system (T46) | Acetyldigitoxin; Acetyldigoxin; Alpha; Alphaacetyldigoxin; Alphaadrenergic blocking drug; Alphaamylase; Alphatocoferol (acetate); Alphatocopherol; b-acetyldigoxin; Cardiotonic (glycoside) NEC; Cerberin; Ch'an su; Convallaria glycosides; Crataegus extract; Cymarin; Deslanoside; Digitalin (e); Digitalis (leaf) (glycoside); Digitalis (leaf) (glycoside)lanata; Digitalis (leaf) (glycoside)purpurea; Dig... |
T46.1X5 | Adverse effect of calcium-channel blockers | Agents primarily affecting the cardiovascular system (T46) | Bepridil; Blockers, calcium channel; Diltiazem; Felodipine; Fendiline; Gallopamil; Iproveratril; Isradipine; Lidoflazine; Monoxidine hydrochloride; Nicardipine; Nifedipine; Nimodipine; Nisoldipine; Nitrendipine; Oxodipine; Tiapamil; Verapamil |
T46.2X5 | Adverse effect of other antidysrhythmic drugs | Agents primarily affecting the cardiovascular system (T46) | Adenosine (phosphate); Ajmaline; Amiodarone; Antidysrhythmic NEC; Aprindine; Bretylium tosilate; Bunaftine; Cardiac; Cardiacdepressants; Cardiacrhythm regulator; Cardiacrhythm regulatorspecified NEC; Chinidin (e); Cibenzoline; Disopyramide; Encainide; Flecainide; Hydroquinidine; Lorajmine; Lorcainide; Mexiletine; Pilsicainide (hydrochloride); Prajmalium bitartrate; Procainamide; Pronestyl (hydroch... |
T46.3X5 | Adverse effect of coronary vasodilators | Agents primarily affecting the cardiovascular system (T46) | Amikhelline; Bendazol; Benziodarone; Carbocromen; Chromonar; Coronary vasodilator NEC; Cromonar; Diisopropylamine; Dilazep; Dimoxyline; Dioxyline; Dipyridamole; Efloxate; Eritrityl tetranitrate; Erythrityl tetranitrate; Erythrol tetranitrate; Etafenone; Fenalcomine; Fluorosol; Heptaminol; Hexadiline; Hexadylamine; Hexobendine; Ipriflavone; Isoamyl nitrite; Isosorbide dinitrate; Itramin tosilate; K... |
T46.4X5 | Adverse effect of angiotensin-converting-enzyme inhibitors | Agents primarily affecting the cardiovascular system (T46) | Alacepril; Benazepril; Captopril; Cilazapril; Enalapril; Enalaprilat; Fosinopril; Fosinoprilsodium; Inhibitor; Inhibitorangiotensin-converting enzyme; Inhibitorcarbonic anhydrase; Inhibitorfibrinolysis; Inhibitormonoamine oxidase NEC; Inhibitormonoamine oxidase NEChydrazine; Inhibitorpostsynaptic; Inhibitorprothrombin synthesis; Lisinopril; Perindopril; Quinapril; Ramipril; Spirapril; Zofenopril |
T46.5X5 | Adverse effect of other antihypertensive drugs | Agents primarily affecting the cardiovascular system (T46) | Aldomet; Alkavervir; Alseroxylon; Amiquinsin; Antihypertensive drug NEC; Apresoline; Benzapril hydrochloride; Betanidine; Bethanidine; Budralazine; Cadralazine; Clonidine; Cryptenamine (tannates); Debrisoquine; Deserpidine; Diazoxide; Dihydralazine; Dihydrazine; Dihydroergotamine; Endralazine; Ergotamine; Guanabenz; Guanacline; Guanadrel; Guanethidine; Guanfacine; Guanochlor; Guanoclor; Guanoctine... |
T46.6X5 | Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs | Agents primarily affecting the cardiovascular system (T46) | Acipimox; Antiarteriosclerotic drug; Anticholesterolemic drug NEC; Antihyperlipidemic drug; Antilipemic drug NEC; Benfluorex; Benzalbutyramide; b-benzalbutyramide; b-sitosterol (s); Bezafibrate; Binifibrate; Cholesterol-lowering agents; Cholestyramine (resin); Ciprofibrate; Clinofibrate; Clofibrate; Clofibride; Clotibric acid; Colestipol; Colestyramine; Cyamopsis tetragono-loba; Detaxtran; Ethylpa... |
T46.7X5 | Adverse effect of peripheral vasodilators | Agents primarily affecting the cardiovascular system (T46) | Alprostadil; Azapetine; Bamethan (sulfate); Bencyclane; Betahistine; Brovincamine; Buflomedil; Buphenine; Butalamine; Cetiedil; Ciclonicate; Cinepazide; Cyclandelate; Dihydroergocornine; Dihydroergocristine (mesilate); Dihydroergokryptine; Dihydroergotoxine; Dihydroergotoxinemesilate; Ergoloid mesylates; Etofylline; Etofyllineclofibrate; Flunarizine; Hepronicate; Hydromethylpyridine; Ifenprodil; I... |
T46.8X5 | Adverse effect of antivaricose drugs, including sclerosing agents | Agents primarily affecting the cardiovascular system (T46) | Antivaricose drug; Ethanolamine oleate; Monoethanolamine; Monoethanolamineoleate; Polidocanol; Sclerosing agent; Sotradecol; Varicose reduction drug; Venous sclerosing drug NEC |
T46.905 | Adverse effect of unspecified agents primarily affecting the cardiovascular system | Agents primarily affecting the cardiovascular system (T46) | Capillary-active drug NEC; Cardiovascular drug NEC |
T46.995 | Adverse effect of other agents primarily affecting the cardiovascular system | Agents primarily affecting the cardiovascular system (T46) | Aconite (wild); Aconitine; Aconitum ferox; Adrenochrome; Adrenochrome (mono) semicarbazone; Adrenochromederivative; Aurantiin; Benzopyrone; Bioflavonoid (s); Chlorisondamine chloride; Diosmin; Escin; Ethoxazorutoside; Flavodic acid; Hesperidin; Leucocianidol; Metescufylline; Naftazone; Phenopyrazone; Pholedrine; Rutinum; Rutoside; Tribenoside; Troxerutin |
T47.0X5 | Adverse effect of histamine H2-receptor blockers | Agents primarily affecting the gastrointestinal system (T47) | Cimetidine; Famotidine; Nizatidine; Ranitidine; Roxatidine |
T47.1X5 | Adverse effect of other antacids and anti-gastric-secretion drugs | Agents primarily affecting the gastrointestinal system (T47) | Alexitol sodium; Algeldrate; Almagate; Almasilate; Aloglutamol; Antacid NEC; Anti-gastric-secretion drug NEC; Benexate; Burimamide; Carbenoxolone; Cetraxate; Chalk, precipitated; Dihydroxyaluminum aminoacetate; Dihydroxyaluminum sodium carbonate; Dimethicone; Dimeticone; Enprostil; Hydrotalcite; Magaldrate; Magnesia magma; Methylpolysiloxane; Metiamide; Milk of magnesia; Misoprostol; Omeprazole; O... |
T47.2X5 | Adverse effect of stimulant laxatives | Agents primarily affecting the gastrointestinal system (T47) | Aloes; Aloin; Bisacodyl; Bisoxatin; Bryonia; Carter's Little Pills; Cascara (sagrada); Chrysazin; Colocynth; Croton (oil); Croton (oil)chloral; Danthron; Dantron; Dianthone; Dihydroxyanthraquinone; Dulcolax; Elaterium; Ex-Lax (phenolphthalein); Frangula; Frangulaextract; Gamboge; Hinkle's pills; Jalap; Oleum ricini; Oxyphenisatine; Phenisatin; Phenolphthalein; Picosulfate (sodium); Rhubarb; Rhubar... |
T47.3X5 | Adverse effect of saline and osmotic laxatives | Agents primarily affecting the gastrointestinal system (T47) | Carbamide; Carbamideperoxide; Carbamidetopical; Epsom salt; Lactulose; Mannitol; Mannitolhexanitrate; Urea; Ureaperoxide; Ureastibamine; Ureatopical |
T47.4X5 | Adverse effect of other laxatives | Agents primarily affecting the gastrointestinal system (T47) | Agar; Atonia drug, intestinal; Bran (wheat); Carboxymethyl-cellulose; Carmellose; Cathartic NEC; Cathartic NECanthacene derivative; Cathartic NECbulk; Cathartic NECcontact; Cathartic NECemollient NEC; Cathartic NECirritant NEC; Cathartic NECmucilage; Cathartic NECsaline; Cathartic NECvegetable; Cellulose; Cellulosecathartic; Cellulosehydroxyethyl; Cellulosenitrates (topical); Celluloseoxidized; Co... |
T47.5X5 | Adverse effect of digestants | Agents primarily affecting the gastrointestinal system (T47) | Amylase; Anise oil; Antiflatulent; b-galactosidase; Betaine; Bile salts; Carminative; Chenodeoxycholic acid; Chenodiol; Cholagogues; Choleretic; Cholic acid; Citric acid; Cytochrome C; Decholin; Dehydrocholic acid; Diastase; Digestant NEC; Dill; Elastase; Florantyrone; b-Galactosidase; Gastric enzymes; Gentian; Gentianviolet; Ginger; GingerJamaica; Glutamic acid; Lipancreatin; Ox bile extract; Pan... |
T47.6X5 | Adverse effect of antidiarrheal drugs | Agents primarily affecting the gastrointestinal system (T47) | Activated charcoal [See Also: Charcoal, medicinal]; Amylopectin; Antidiarrheal drug NEC; Antidiarrheal drug NECabsorbent; Attapulgite; Bismuth salts; Bismuth saltsaluminate; Bismuth saltsanti-infectives; Bismuth saltsformic iodide; Bismuth saltsglycolylarsenate; Bismuth saltsnonmedicinal (compounds) NEC; Bismuth saltssubcarbonate; Bismuth saltssubsalicylate; Bismuth saltssulfarsphenamine; Carbo me... |
T47.7X5 | Adverse effect of emetics | Agents primarily affecting the gastrointestinal system (T47) | Apomorphine; Emetic NEC; Ipecac; Mustard (emetic); Mustard (emetic)black; Mustard (emetic)gas, not in war; Mustard (emetic)nitrogen |
T47.8X5 | Adverse effect of other agents primarily affecting gastrointestinal system | Agents primarily affecting the gastrointestinal system (T47) | Algin; Bacillus; Bacilluslactobacillus; Bacillussubtilis; Bromopride; Carrageenan; Cisapride; Clebopride; Glucurolactone; Hepatic secretion stimulant; Ion exchange resin; Ion exchange resinanion; Ion exchange resincation; Ion exchange resincholestyramine; Ion exchange resinintestinal; Mesalazine; Olsalazine; Pancreatic; Pancreaticdigestive secretion stimulant; Pancreaticdornase; Polysilane; Sulfat... |
T47.95 | Adverse effect of unspecified agents primarily affecting the gastrointestinal system | Agents primarily affecting the gastrointestinal system (T47) | Gastrointestinal drug; Gastrointestinal drugbiological; Gastrointestinal drugspecified NEC |
T48.0X5 | Adverse effect of oxytocic drugs | Agents prim act on smooth and skeletal musc and the resp sys (T48) | Carboprost; Dinoprost; Dinoprostone; Ergobasine; Ergometrine; Ergonovine; Ergotocine; Ergotrate; Gemeprost; Methergine; Methylergometrine; Methylergonovine; Oxytocic drug NEC; Oxytocin (synthetic); Pitocin; Sparteine; Sulprostone; Syntocinon; Tocosamine; Vetrabutine |
T48.1X5 | Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents] | Agents prim act on smooth and skeletal musc and the resp sys (T48) | Aclatonium napadisilate; Alcuronium (chloride); Atracurium besilate; Carbolonium (bromide); Curare, curarine; Cyclobenzaprine; Decamethonium (bromide); Dimethyltubocurarinium chloride; Fazadinium bromide; Flaxedil; Gallamine (triethiodide); Hexafluorenium bromide; Hexafluronium (bromide); Hexanuorenium; Hexcarbacholine bromide; Laudexium; Mivacurium chloride; Myoneural blocking agents; Neuromuscul... |
T48.205 | Adverse effect of unspecified drugs acting on muscles | Agents prim act on smooth and skeletal musc and the resp sys (T48) | Muscle-action drug NEC; Muscle affecting agents NEC; Muscle affecting agents NECoxytocic; Muscle affecting agents NECrelaxants; Muscle affecting agents NECrelaxantscentral nervous system; Muscle affecting agents NECrelaxantsskeletal; Muscle affecting agents NECrelaxantssmooth |
T48.295 | Adverse effect of other drugs acting on muscles | Agents prim act on smooth and skeletal musc and the resp sys (T48) | Botox; Bruceine; Dipropyline; Hydrastine; Lututrin; Metaproterenol; Orciprenaline |
T48.3X5 | Adverse effect of antitussives | Agents prim act on smooth and skeletal musc and the resp sys (T48) | Antitussive NEC; Antitussive NECcodeine mixture; Antitussive NECopiate; Benproperine; Benzonatate; Bibenzonium bromide; Butamirate; Carbetapentane; Chlophedianol; Clobutinol; Clofedanol; Cloperastine; Clophedianol; Dextromethorphan; Dibunate sodium; Dimemorfan; Dimethoxanate; Dropropizine; Fedrilate; Fominoben; Isoaminile (citrate); Levdropropizine; Methorate; Narcotine; Nectadon; Noscapine; Oxela... |
T48.4X5 | Adverse effect of expectorants | Agents prim act on smooth and skeletal musc and the resp sys (T48) | Acetylcysteine; Ambroxol; Bromhexine; Carbocisteine; S-Carboxymethyl-cysteine; Cough mixture (syrup); Cough mixture (syrup)containing opiates; Cough mixture (syrup)expectorants; Deglycyrrhizinized extract of licorice; Domiodol; Dornase; Eprazinone; Expectorant NEC; Glyceryl; Glycerylgualacolate; Glycerylnitrate; Glyceryltriacetate (topical); Glyceryltrinitrate; Glycyrrhiza extract; Glycyrrhizic ac... |
T48.5X5 | Adverse effect of other anti-common-cold drugs | Agents prim act on smooth and skeletal musc and the resp sys (T48) | Amidefrine mesilate; Anti-common-cold drug NEC; APC; Benzoin (tincture); Cinnamedrine; Contac; Decongestant, nasal (mucosa); Decongestant, nasal (mucosa)combination; Fenoxazoline; Indanazoline; Menthol; Metizoline; Naphazoline; Oxymetazoline; Propylhexedrine; Tramazoline; Tuaminoheptane; Tymazoline; Xylometazoline |
T48.6X5 | Adverse effect of antiasthmatics | Agents prim act on smooth and skeletal musc and the resp sys (T48) | Acefylline piperazine; Acepifylline; Albuterol; Ambuphylline; Aminophylline; Amlexanox; Antiasthmatic drug NEC; Bambuterol; Bamifylline; Bitolterol; Bronchodilator NEC; Broxaterol; Bufrolin; Bufylline; Butetamate; Carbuterol; Choline; Cholinechloride; Cholinedihydrogen citrate; Cholinesalicylate; Cholinetheophyllinate; Clenbuterol; Clorprenaline; Cromoglicic acid; Cromolyn; Doxantrazole; Enprofyll... |
T48.905 | Adverse effect of unspecified agents primarily acting on the respiratory system | Agents prim act on smooth and skeletal musc and the resp sys (T48) | Respiratory drug NEC; Respiratory drug NECantiasthmatic NEC; Respiratory drug NECanti-common-cold NEC; Respiratory drug NECexpectorant NEC; Respiratory drug NECstimulant |
T49.0X5 | Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs | Topical skin/eye/ENT/dental drugs (T49) | Acriflavinium chloride; Acrinol; Acrisorcin; Akrinol; Alclometasone; Alkonium (bromide); Allethrin; Amcinonide; Aminacrine; Aminoacridine; Ammoniated mercury; Antiseptics (external) (medicinal); Argyrol; ArgyrolENT agent; Argyrolophthalmic preparation; Asiaticoside; Azelaic acid; Bacimycin; Bacimycinophthalmic preparation; Bacitracin zinc; Bacitracin zincwith neomycin; Bacitracin zincENT agent; Ba... |
T49.1X5 | Adverse effect of antipruritics | Topical skin/eye/ENT/dental drugs (T49) | Antipruritic drug NEC; b-eucaine; Dimethisoquin; ESDT (ether-soluble tar distillate); Juniper tar; Phenolic preparation; Pramocaine; Pramoxine; Quinisocaine |
T49.2X5 | Adverse effect of local astringents and local detergents | Topical skin/eye/ENT/dental drugs (T49) | Aluminium, aluminum; Aluminium, aluminumacetate; Aluminium, aluminumacetatesolution; Aluminium, aluminumaspirin; Aluminium, aluminumbis (acetylsalicylate); Aluminium, aluminumcarbonate (gel, basic); Aluminium, aluminumchlorhydroxide-complex; Aluminium, aluminumchloride; Aluminium, aluminumclofibrate; Aluminium, aluminumdiacetate; Aluminium, aluminumglycinate; Aluminium, aluminumhydroxide (gel); Al... |
T49.3X5 | Adverse effect of emollients, demulcents and protectants | Topical skin/eye/ENT/dental drugs (T49) | Acrylic resin; Allylthiourea; Aminobenzoic acid (-p); Arachis oil; Arachis oilcathartic; Barrier cream; Bentonite; Benzophenones; Betula oil; Calamine (lotion); Carbowax; Chlordiethyl benzamide; Cold cream; Collodion; Colophony adhesive; Corn starch; Cornhusker's lotion; Cottonseed oil; Cyanoacrylate adhesive; Demulcent (external); Demulcent (external)specified NEC; Emollient NEC; Filtering cream;... |
T49.4X5 | Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations | Topical skin/eye/ENT/dental drugs (T49) | Allantoin; Alum (medicinal); Alum (medicinal)nonmedicinal (ammonium) (potassium); Anthralin; Antiseborrheics; Bleaching agent (medicinal); Butantrone; Cade oil; Capsicum; Carbazochrome (salicylate) (sodium sulfonate); Chlorothymol; Chloroxine; Chrysarobin; Collagenase; Corn cures; Depilatory; Desloughing agent; Diachylon plaster; Dimethylamine sulfate; Dithranol; Euresol; Flowers of sulfur; Fumari... |
T49.5X5 | Adverse effect of ophthalmological drugs and preparations | Topical skin/eye/ENT/dental drugs (T49) | Ammonium; Ammoniumacid tartrate; Ammoniumbromide; Ammoniumcarbonate; Ammoniumchloride; Ammoniumchlorideexpectorant; Ammoniumcompounds (household) NEC; Ammoniumcompounds (household) NECfumes (any usage); Ammoniumcompounds (household) NECindustrial; Ammoniumichthyosulronate; Ammoniummandelate; Ammoniumsulfamate; Ammoniumsulfonate resin; Befunolol; Bibrocathol; Chloroptic; Contact lens solution; Cycl... |
T49.6X5 | Adverse effect of otorhinolaryngological drugs and preparations | Topical skin/eye/ENT/dental drugs (T49) | Alkaline antiseptic solution (aromatic); Ambazone; Amylmetacresol; Biclotymol; Bisdequalinium (salts) (diacetate); Corbadrine; Dichlorobenzyl alcohol; Ear drug NEC; Ear preparations; ENT preparations (anti-infectives); Levonordefrin; Lozenges (throat); Mouthwash (antiseptic) (zinc chloride); Nasal drug NEC; Nose preparations; Otorhinolaryngological drug NEC; Thenoic acid; Throat drug NEC; Tyrothri... |
T49.7X5 | Adverse effect of dental drugs, topically applied | Topical skin/eye/ENT/dental drugs (T49) | Dental drug, topical application NEC; Dentifrice; Dressing, live pulp; Eucalyptus oil; Fluoristan; Pulp; Pulpdevitalizing paste; Pulpdressing; Stannous fluoride |
T49.8X5 | Adverse effect of other topical agents | Topical skin/eye/ENT/dental drugs (T49) | Benoquin; Cantharides, cantharidin, cantharis; Cell stimulants and proliferants; Chloresium; Cosmetic preparation; Cosmetics; Demelanizing agents; Deodorant spray (feminine hygiene); Elase; Gelfilm; Heet; Irrigating fluid (vaginal); Irrigating fluid (vaginal)eye; Lactic acid; Local action drug NEC; Lytta (vitatta); Nonoxinol; Nonylphenoxy (polyethoxy-ethanol); Octoxinol (9); Podophyllotoxin; Prepa... |
T49.95 | Adverse effect of unspecified topical agent | Topical skin/eye/ENT/dental drugs (T49) | External medications (skin) (mucous membrane); External medications (skin) (mucous membrane)dental agent; External medications (skin) (mucous membrane)ENT agent; External medications (skin) (mucous membrane)ophthalmic preparation; External medications (skin) (mucous membrane)specified NEC; Liniments NEC; Lotions NEC; Mucous membrane agents (external); Mucous membrane agents (external)specified NEC... |
T50.0X5 | Adverse effect of mineralocorticoids and their antagonists | Diuretics and oth and unsp drug/meds/biol subst (T50) | Aldactone; Aldosterone; Antagonist; AntagonistAldosterone; Antagonistalpha-adrenoreceptor; Antagonistanticoagulant; Antagonistbeta-adrenoreceptor; Antagonistextrapyramidal NEC; Antagonistfolic acid; AntagonistH2 receptor; Antagonistheavy metal; Antagonistnarcotic analgesic; Antagonistopiate; Antagonistpyrimidine; Antagonistserotonin; Canrenoic acid; Canrenone; Deoxycortone; Desoxycorticosteroid; D... |
T50.1X5 | Adverse effect of loop [high-ceiling] diuretics | Diuretics and oth and unsp drug/meds/biol subst (T50) | Bumetanide; Edecrin; Etacrynate sodium; Etacrynic acid; Ethacrynic acid; Etozolin; Frusemide; Furosemide; Lasix; Lyovac Sodium Edecrin; Piretanide; Ticrynafen; Tienilic acid |
T50.2X5 | Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics | Diuretics and oth and unsp drug/meds/biol subst (T50) | Acetazolamide; Altizide; Amiloride; Aminometradine; Amisometradine; Anhydron; Bendrofluazide; Bendroflumethiazide; Benzothiadiazides; Benzthiazide; Benzylhydrochlorthia-zide; Butizide; Cardrase; Chlorazanil; Chlormerodrin; Chlorothiazide; Chlortalidone; Chlorthalidone; Clofenamide; Clopamide; Clorexolone; Cyclopenthiazide; Cyclothiazide; Diamox; Dichlorphenamide; Diclofenamide; Dihydroxypropyl the... |
T50.3X5 | Adverse effect of electrolytic, caloric and water-balance agents | Diuretics and oth and unsp drug/meds/biol subst (T50) | Amino acids; Aminoacetic acid (derivatives); Antikaluretic; Calcium; Calciumactylsalicylate; Calciumbenzamidosalicylate; Calciumbromide; Calciumbromolactobionate; Calciumcarbaspirin; Calciumcarbimide; Calciumcarbonate; Calciumchloride; Calciumchlorideanhydrous; Calciumcyanide; Calciumdioctyl sulfosuccinate; Calciumdisodium edathamil; Calciumdisodium edetate; Calciumdobesilate; CalciumEDTA; Calcium... |
T50.4X5 | Adverse effect of drugs affecting uric acid metabolism | Diuretics and oth and unsp drug/meds/biol subst (T50) | Allopurinol; Atophan; Benemid; Benzbromarone; Cinchophen; Colchicine; Etebenecid; Ethebenecid; Neocinchophen; Oxipurinol; Phenoquin; Probenecid; Spindle inactivator; Sulfinpyrazone; Sulphinpyrazone; Tisopurine; Urate oxidase; Uric acid metabolism drug NEC; Uricosuric agent |
T50.5X5 | Adverse effect of appetite depressants | Diuretics and oth and unsp drug/meds/biol subst (T50) | Amfepramone; Aminorex; Anorexiant (central); Anorexic agents; Appetite depressants, central; Benzamphetamine; Benzfetamine; Benzphetamine; Bulk filler; Bulk fillercathartic; Cathine; Chlorphentermine; Clobenzorex; Cloforex; Clortermine; Depressant, appetite; Depressant; Depressantappetite (central); Depressantcardiac; Depressantcentral nervous system (anesthetic) [See Also: Central nervous system,... |
T50.6X5 | Adverse effect of antidotes and chelating agents | Diuretics and oth and unsp drug/meds/biol subst (T50) | Antabuse; Antidote NEC; Antidote NECheavy metal; Chelating agent NEC; Cholinesterase reactivator; Cysteamine; Deterrent, alcohol; Detoxifying agent; Disodium edetate; Disulfiram; EDTA; Ethylenediaminetetra-acetic acid; Ethylenedinitrilotetra-acetate; Fytic acid, nonasodium; Glutathione; Methylene; Methyleneblue; Methylenechloride or dichloride (solvent) NEC; Methylthionine chloride; Methylthionini... |
T50.7X5 | Adverse effect of analeptics and opioid receptor antagonists | Diuretics and oth and unsp drug/meds/biol subst (T50) | Almitrine; Amiphenazole; Analeptic NEC; Bemegride; Bicucculine; Cyclazocine; Dimefline; Dimorpholamine; Doxapram; Etamivan; Ethamivan; Leptazol; Levallorphan; Lobeline; Nalorphine; Naloxone; Naltrexone; Nikethamide; Pemoline; Pentetrazole; Pentylenetetrazole; Picrotoxin; Pimeclone; Prethcamide |
T50.8X5 | Adverse effect of diagnostic agents | Diuretics and oth and unsp drug/meds/biol subst (T50) | Acetrizoate (sodium); Acetrizoic acid; Adipiodone; Ametazole; Amidotrizoate; Aminohippuric acid; Angio-Conray; Azuresin; Bentiromide; Betazole; Biligrafin; Bilopaque; Bromsulfophthalein; Bunamiodyl; Cardiografin; Cardio-green; Ceruletide; Cholebrine; Cholecystokinin; Cholografin; Coccidioidin; Congo red; Contrast medium, radiography; Diagnostic agent NEC; Diatrizoate; Diodone; Ethiodized oil (131 ... |
T50.905 | Adverse effect of unspecified drugs, medicaments and biological substances | Diuretics and oth and unsp drug/meds/biol subst (T50) | Acidifying agent NEC; Adjunct, pharmaceutical; Alkalinizing agents (medicinal); Alkalizing agent NEC; Biological substance NEC; Dietetic drug NEC; Drug NEC; Drug NECspecified NEC; Elemental diet; Excipients, pharmaceutical; Headache cures, drugs, powders NEC; Lactose (as excipient); Lipotropic drug NEC; Medicament NEC; Nutritional supplement; Pharmaceutical; Pharmaceuticaladjunct NEC; Pharmaceutic... |
T50.915 | Adverse effect of multiple unspecified drugs, medicaments and biological substances | Diuretics and oth and unsp drug/meds/biol subst (T50) | Multiple unspecified drugs, medicaments and biological substances |
T50.995 | Adverse effect of other drugs, medicaments and biological substances | Diuretics and oth and unsp drug/meds/biol subst (T50) | Acetohydroxamic acid; Acitretin; Arginine; Arginineglutamate; Baking soda; Bergapten; BHA; Bromophenol blue reagent; Butylated hydroxy-anisole; Calcitonin; Calculus-dissolving drug; Canthaxanthin; Cetomacrogol; Chlorophyll; Cianidanol; Clodronic acid; Coenzyme A; Cogalactoiso-merase; Collagen; Colorant [See Also: Dye]; Cyclamate; Deanol (aceglumate); Elcatonin; Epomediol; Etidronate; Etidronic aci... |
T50.A25 | Adverse effect of mixed bacterial vaccines without a pertussis component | Diuretics and oth and unsp drug/meds/biol subst (T50) | Toxoid; Toxoidcombined; Toxoiddiphtheria; Toxoidtetanus |
T50.A95 | Adverse effect of other bacterial vaccines | Diuretics and oth and unsp drug/meds/biol subst (T50) | BCG (vaccine); Cholera vaccine; Meningococcal vaccine; Menningovax (-AC) (-C); Paratyphoid vaccine; Plague vaccine; Rickettsial vaccine NEC; Rocky Mountain spotted fever vaccine; Tetanus toxoid or vaccine; Tetanus toxoid or vaccineantitoxin; Tetanus toxoid or vaccineimmune globulin (human); Tetanus toxoid or vaccinetoxoid; Tetanus toxoid or vaccinetoxoidwith diphtheria toxoid; Tetanus toxoid or va... |
T50.B15 | Adverse effect of smallpox vaccines | Diuretics and oth and unsp drug/meds/biol subst (T50) | Smallpox vaccine |
T50.B95 | Adverse effect of other viral vaccines | Diuretics and oth and unsp drug/meds/biol subst (T50) | Diplovax; Influenza vaccine; Measles virus vaccine (attenuated); Meruvax; Mumpsvax; Orimune; Poliomyelitis vaccine; Rubella vaccine; Rubeola vaccine; Synagis; Viral vaccine NEC; Yellow; Yellowfever vaccine; Yellowjasmine; Yellowphenolphthalein |
T50.Z15 | Adverse effect of immunoglobulin | Diuretics and oth and unsp drug/meds/biol subst (T50) | AHLG; Anti-D immunoglobulin (human); Antidiphtheria serum; Anti-human lymphocytic globulin; Antirabies hyperimmune serum; Antiscorpion sera; Antitetanus immunoglobulin; Antitoxin; Antitoxindiphtheria; Antitoxingas gangrene; Antitoxintetanus; Antivenin, antivenom (sera); Antivenin, antivenom (sera)crotaline; Antivenin, antivenom (sera)spider bite; Botulinus anti-toxin (type A, B); Diphtheria; Dipht... |
T50.Z95 | Adverse effect of other vaccines and biological substances | Diuretics and oth and unsp drug/meds/biol subst (T50) | Glandular extract (medicinal) NEC; Pegademase, bovine; Vaccine NEC; Vaccine NECantineoplastic; Vaccine NECbacterial NEC; Vaccine NECbacterial NECwith; Vaccine NECbacterial NECwithother bacterial component; Vaccine NECbacterial NECwithpertussis component; Vaccine NECbacterial NECwithviral-rickettsial component; Vaccine NECbacterial NECmixed NEC; Vaccine NECBCG; Vaccine NECcholera; Vaccine NECdiphth... |